Skip to Main Content

Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source.


The Vera and Joseph Dresner Foundation MDS Research Fund
The fund will facilitate the advancement of innovative basic science, translational or clinical research to advance the understanding and treatment of Myelodysplastic Syndromes (MDS) and related blood disorders (such as MDS/myeloproliferative neoplasms (MPN) overlap syndromes, secondary acute myeloid leukemia following MDS, idiopathic cytopenia of undetermined significance (ICUS), or clonal hematopoiesis of indeterminate potential (CHIP).

The foundation will consider proposals from individuals at university, college, hospital, or laboratory institutions for support of research in MDS or related disorders in two types:
- Early Career Awards
- Established Investigator Awards

Letter of Intent (LOI) Deadline: LOIs are accepted on a rolling basis.
Learn More>>

Fast Funding for COVID-19 Science

If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant.

Deadline: Fast Grant decisions are made in under 48 hours. Apply Now!

Apply for a Fast Funding grant now>>

DoD Lung Cancer Research Program Funding Opportunities

The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense LCRP to support innovative, high-impact lung cancer research.

Investigator-Initiated Translational Research Award - Pre-proposal Due: May 5, 2021
Clinical Translational Research Partnership Award - LOI Due: July 14, 2021

NCCN Request for Proposals (RFP): Phase I/II Clinical and/or Correlative Studies of the panHER Inhibitor Neratinib in the Treatment of Breast, Gastrointestinal, Lung, and Neurological Cancers

This RFP is to support NCCN Member Institution faculty for the performance of clinical and correlative studies to further evaluate the effectiveness of neratinib in the treatment of breast, gastrointestinal (GI), lung and neurological cancers.

Application Deadline: April 19, 2021

Cancer Grand Challenges Program

The NCI and Cancer Research UK (CRUK) are partnering to fund the Cancer Grand Challenges program. Cancer Grand Challenges will fund novel ideas by multidisciplinary research teams from around the world that offer the potential to advance bold cancer research and improve outcomes for people affected by cancer. These nine challenges are aimed at solving complex problems in cancer research, which, if solved, could have a transformative impact towards progress.

Application Deadline: April 22, 2021

Alex's Lemonade Stand - Crazy 8 Initiative

This initiative aims to tackle specific challenges in pediatric cancer research that require substantial support for collaborative teams. The Crazy 8 Initiative will fund research into innovative and rigorous approaches that directly address the most intractable issues in pediatric cancer research today.

Letter of Intent Due: April 26, 2021

NCCN/AstraZeneca Initiative RFP in Patients with Early Stage Non-Small Cell Lung Cancer (NSCLC)

The intent of this RFP is to encourage NCCN Member Institutions to submit letters of intent (LOIs) describing concepts and ideas for developing, implementing and evaluating healthcare provider performance and/or healthcare quality improvement initiatives to improve patient care and outcomes in early-stage NSCLC.

Letter of Intent Deadline: May 3, 2021

Pfizer Global Medical Grants - NSCLC Therapy Management for Optimal Outcomes

Projects that will be considered for Pfizer support will focus on development of an algorithm or tool to guide the optimal treatment and support of patients with ALK or ROS1 re-arranged NSCLC.

Application Deadline: May 5, 2021

NCCN/Pfizer/Astellas Request for Proposals (RFP): Enzalutamide in the Treatment of Prostate Cancer

The overall aim of this RFP is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer.

Letter of Intent Due: May 14, 2021

The Cure Starts Now Foundation Research Grants

Research questions considered - Disease Impact: Does the study propose an intervention or clinical tool that will reduce the morbidity or mortality from or potentially find a cure for pediatric brain cancer? Innovation: Does the research study propose a novel approach or represent advancement in current treatment of pediatric brain cancer?

Application Deadline: June 1, 2021

Breast Cancer Alliance Young Investigator Grant

To encourage a commitment to breast cancer research, the BCA invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers to apply for funding for the Young Investigator Grant.

Internal LOI Deadline: June 1, 2021

Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program

The BMSF DCTCDP is a 2-year program designed to support the career development of early-stage investigator (as defined by NIH) physicians underrepresented in medicine, or physicians who have a demonstrated commitment to increasing diversity in clinical research, to become independent clinical trial investigators who are engaged in advancing health equity through their research and mentoring.

Application Deadline: July 2, 2021

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01)

This FOA supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries.

Application Deadline: June 2, 2021

Tobacco Regulatory Science (R01)

The purpose of this FOA is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

Application Deadline: July 14, 2021